ToremifeneEstrogen-receptor modulator CAS# 89778-26-7 |
- Fulvestrant
Catalog No.:BCC1081
CAS No.:129453-61-8
- (Z)-2-decenoic acid
Catalog No.:BCC1295
CAS No.:15790-91-7
- Bazedoxifene
Catalog No.:BCC1411
CAS No.:198481-32-2
- Bazedoxifene acetate
Catalog No.:BCC1412
CAS No.:198481-33-3
- (E)-2-Decenoic acid
Catalog No.:BCC1292
CAS No.:334-49-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 89778-26-7 | SDF | Download SDF |
PubChem ID | 3005573 | Appearance | Powder |
Formula | C26H28ClNO | M.Wt | 405.96 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | 25℃: DMSO 120mg/mL ;Water <1mg/mL; Ethanol <1mg/mL | ||
Chemical Name | 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine | ||
SMILES | CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3 | ||
Standard InChIKey | XFCLJVABOIYOMF-QPLCGJKRSA-N | ||
Standard InChI | InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Toremifene Dilution Calculator
Toremifene Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4633 mL | 12.3165 mL | 24.633 mL | 49.2659 mL | 61.5824 mL |
5 mM | 0.4927 mL | 2.4633 mL | 4.9266 mL | 9.8532 mL | 12.3165 mL |
10 mM | 0.2463 mL | 1.2316 mL | 2.4633 mL | 4.9266 mL | 6.1582 mL |
50 mM | 0.0493 mL | 0.2463 mL | 0.4927 mL | 0.9853 mL | 1.2316 mL |
100 mM | 0.0246 mL | 0.1232 mL | 0.2463 mL | 0.4927 mL | 0.6158 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50 Value: 1±0.3μM. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis and other adverse effects resulting from ADT in men with prostate cancer [1]. in vitro: The growth of Ac-1 cells was inhibited by tamoxifen, toremifene and atamestane in vitro with IC50values of 1.8±1.3μM, 1±0.3μM and 60.4±17.2μM, respectively. The combination of toremifene plusatamestane was found to be better than toremifene or atamestane alone in vitro[2]. in vivo: The effect of this combination was then studied in vivo using Ac-1 xenografts grown in ovariectomized female SCID mice. The mice were injected with toremifene (1000μg/day), atamestane (1000μg/day), tamoxifen (100μg/day), or the combination of toremifene plus atamestane. In this study, our results indicate that the combination of toremifene plus atamestane was as effective as toremifene or tamoxifen alone but may not provide any additional benefit over toremifene alone or tamoxifen alone[2]. Clinical trial: Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene[3].
- AST-1306
Catalog No.:BCC3727
CAS No.:897383-62-9
- 7-O-Acetyl-4-O-demethylpolysyphorin
Catalog No.:BCN3984
CAS No.:89706-39-8
- KX2-391
Catalog No.:BCC5080
CAS No.:897016-82-9
- Androstadienedione
Catalog No.:BCC8824
CAS No.:897-06-3
- VX-11e
Catalog No.:BCC2051
CAS No.:896720-20-0
- BMH-21
Catalog No.:BCC5580
CAS No.:896705-16-1
- AT9283
Catalog No.:BCC2173
CAS No.:896466-04-9
- trans-3-Oxo-alpha-ionol
Catalog No.:BCN3385
CAS No.:896107-70-3
- Imiquimod maleate
Catalog No.:BCC4197
CAS No.:896106-16-4
- 2-Acetamidoethyl phosphate
Catalog No.:BCN1760
CAS No.:89603-45-2
- Chamaejasmenin A
Catalog No.:BCN3044
CAS No.:89595-71-1
- Chamaejasmenin C
Catalog No.:BCN3043
CAS No.:89595-70-0
- Toremifene Citrate
Catalog No.:BCC4487
CAS No.:89778-27-8
- Tazobactam acid
Catalog No.:BCC9160
CAS No.:89786-04-9
- 2,3,24-Trihydroxy-12-ursen-28-oic acid
Catalog No.:BCN1314
CAS No.:89786-83-4
- Myrianthic acid
Catalog No.:BCN7130
CAS No.:89786-84-5
- Aceclofenac
Catalog No.:BCC5233
CAS No.:89796-99-6
- 5-Ethyltio-1H-Tetrazole
Catalog No.:BCC2844
CAS No.:89797-68-2
- PF-3758309
Catalog No.:BCC1853
CAS No.:898044-15-0
- YS-035 hydrochloride
Catalog No.:BCC6639
CAS No.:89805-39-0
- Esculentoside D
Catalog No.:BCN5013
CAS No.:89808-50-4
- XL228
Catalog No.:BCC2058
CAS No.:898280-07-4
- 4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one hydrochloride
Catalog No.:BCC8647
CAS No.:898543-06-1
- 3-Epichromolaenide
Catalog No.:BCN7241
CAS No.:89913-53-1
Repurposing Toremifene for Treatment of Oral Bacterial Infections.[Pubmed:27993858]
Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: AAC.01846-16.
The spread of antibiotic resistance and the challenges associated with antiseptics such as chlorhexidine have necessitated a search for new antibacterial agents against oral bacterial pathogens. As a result of failing traditional approaches, drug repurposing has emerged as a novel paradigm to find new antibacterial agents. In this study, we examined the effects of the FDA-approved anticancer agent Toremifene against the oral bacteria Porphyromonas gingivalis and Streptococcus mutans We found that the drug was able to inhibit the growth of both pathogens, as well as prevent biofilm formation, at concentrations ranging from 12.5 to 25 muM. Moreover, Toremifene was shown to eradicate preformed biofilms at concentrations ranging from 25 to 50 muM. In addition, we found that Toremifene prevents P. gingivalis and S. mutans biofilm formation on titanium surfaces. A time-kill study indicated that Toremifene is bactericidal against S. mutans Macromolecular synthesis assays revealed that treatment with Toremifene does not cause preferential inhibition of DNA, RNA, or protein synthesis pathways, indicating membrane-damaging activity. Biophysical studies using fluorescent probes and fluorescence microscopy further confirmed the membrane-damaging mode of action. Taken together, our results suggest that the anticancer agent Toremifene is a suitable candidate for further investigation for the development of new treatment strategies for oral bacterial infections.
Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients.[Pubmed:27240168]
Breast. 2016 Aug;28:67-72.
BACKGROUND AND AIM: The aim of this study was to identify the effect of selective estrogen receptor modulator (SERM) on non-alcoholic fatty liver disease (NAFLD) in Asian women. METHODS: We retrospectively evaluated fatty liver development and/or serum alanine aminotransferase (ALT) elevation during SERM treatment in 1061 women who were diagnosed and treated with breast cancer in 2005 at Asan Medical Center. RESULTS: 45 of 618 SERM-treated patients with normal ALT at baseline experienced ALT elevation during SERM treatment. Among the 112 SERM-treated patients who underwent liver imaging test, fatty liver was observed in 47 and both fatty liver and ALT elevation developed in 16 of 102 SERM-treated patients with normal baseline ALT. The cumulative rates of ALT elevation (10.7 vs. 4.3%; P = 0.002), fatty liver (48.5 vs. 20.9%; P < 0.001), and both fatty liver and ALT elevation (17.7 vs. 7.1%; P = 0.02) at 60 months were significantly higher in the SERM group than non-SERM group. By multivariate analysis, SERM treatment increased the risk of ALT elevation (hazard ratio [HR], 2.20; P = 0.01), fatty liver development (HR, 3.59; P < 0.001), and both fatty liver and ALT elevation (HR, 4.98; P = 0.01). After discontinuation of SERM, elevated serum ALT normalized in 39 (92.9%) and there were no instances of liver-related death or progression to liver cirrhosis in patients who experienced fatty liver or ALT elevation. CONCLUSIONS: Although SERM treatment is significantly associated with NAFLD in Asian women, considering the tolerability and reversibility of NAFLD induced by SERM, it can be continued with liver function monitoring in relevant patients.
Toremifene interacts with and destabilizes the Ebola virus glycoprotein.[Pubmed:27362232]
Nature. 2016 Jul 7;535(7610):169-172.
Ebola viruses (EBOVs) are responsible for repeated outbreaks of fatal infections, including the recent deadly epidemic in West Africa. There are currently no approved therapeutic drugs or vaccines for the disease. EBOV has a membrane envelope decorated by trimers of a glycoprotein (GP, cleaved by furin to form GP1 and GP2 subunits), which is solely responsible for host cell attachment, endosomal entry and membrane fusion. GP is thus a primary target for the development of antiviral drugs. Here we report the first, to our knowledge, unliganded structure of EBOV GP, and high-resolution complexes of GP with the anticancer drug Toremifene and the painkiller ibuprofen. The high-resolution apo structure gives a more complete and accurate picture of the molecule, and allows conformational changes introduced by antibody and receptor binding to be deciphered. Unexpectedly, both Toremifene and ibuprofen bind in a cavity between the attachment (GP1) and fusion (GP2) subunits at the entrance to a large tunnel that links with equivalent tunnels from the other monomers of the trimer at the three-fold axis. Protein-drug interactions with both GP1 and GP2 are predominately hydrophobic. Residues lining the binding site are highly conserved among filoviruses except Marburg virus (MARV), suggesting that MARV may not bind these drugs. Thermal shift assays show up to a 14 degrees C decrease in the protein melting temperature after Toremifene binding, while ibuprofen has only a marginal effect and is a less potent inhibitor. These results suggest that inhibitor binding destabilizes GP and triggers premature release of GP2, thereby preventing fusion between the viral and endosome membranes. Thus, these complex structures reveal the mechanism of inhibition and may guide the development of more powerful anti-EBOV drugs.
[A Case of Liver Failure Induced by Toremifene in a Patient with Metastatic Breast Cancer].[Pubmed:26805180]
Gan To Kagaku Ryoho. 2015 Nov;42(12):1809-11.
A 67-year-old woman underwent total mastectomy, postoperative radiation therapy, and adjuvant hormonal therapy more than 9 years 4 months previously. There were no symptoms of recurrence for 3.5 years after completing adjuvant hormonal therapy. A hard mass appeared on the front chest wall and was diagnosed as recurrence of breast cancer histopathologically. A computed tomography (CT) scan revealed multiple metastases in the left side of the chest wall, in the left Level axillary lymph nodes, and in the left lung. The patient was prescribed high-dose tremifene (HD-TOR 120 mg/day). After less than 4 months, she presented with general fatigue and yellow skin, and was admitted with grade 4 hyperbilirubinemia and grade 3 hepatic dysfunction (AST and ALT). CT and magnetic resonance imaging (MRI) showed no abnormal findings in the liver or biliary tract. Drug-induced liver injury (DILI) caused by HD-TOR was suspected and this therapy was discontinued. The liver dysfunction showed a tendency to improve with conservative treatment and the patient was discharged on the 10th day of illness. She had almost recovered after 5.5 months. A liver biopsy, a drug-lymphocyte stimulation test, and other detailed examinations were not performed, but we judged this case to be one of liver failure caused by HD-TOR-induced DILI.